Abstract: Disclosed herein are topical compositions of 5-? reductase inhibitors, such as dutasteride or finasteride, or a pharmaceutically acceptable salt, ester, or derivative thereof and the use of the compositions for the treatment of hair loss secondary to endocrine therapy in patients with breast cancer (Endocrine Therapy-Induced Alopecia or ETIA), androgenetic alopecia (AGA), alopecia areata, and hirsutism. The topical composition is advantageous over the existing oral compositions of 5-? reductase inhibitors because the topical composition is safer and more effective. The topical formulation may allow for a slow release of the active ingredient dutasteride, better penetration at the therapeutically effective amount of dutasteride with an improved safety profile because it does not need to travel through the bloodstream to be efficacious, thereby minimizing the risk of systemic side effects.

Abstract: Disclosed herein are topical compositions of 5-? reductase inhibitors, such as dutasteride or finasteride, or a pharmaceutically acceptable salt, ester, or derivative thereof and the use of the compositions for the treatment of hair loss secondary to endocrine therapy in patients with breast cancer (Endocrine Therapy-Induced Alopecia or ETIA), androgenetic alopecia (AGA), alopecia areata, and hirsutism. The topical composition is advantageous over the existing oral compositions of 5-? reductase inhibitors because the topical composition is safer and more effective. The topical formulation may allow for a slow release of the active ingredient dutasteride, better penetration at the therapeutically effective amount of dutasteride with an improved safety profile because it does not need to travel through the bloodstream to be efficacious, thereby minimizing the risk of systemic side effects.

Abstract: The invention features topical dutasteride emulsions for local delivery to the dermis of a subject suffering from hair loss, such as hair loss secondary to endocrine therapy in patients with breast cancer.

Abstract: The invention features topical dutasteride emulsions for local delivery to the dermis of a subject suffering from hair loss, such as hair loss secondary to endocrine therapy in patients with breast cancer.

Abstract: A system and methods for patient care reconnaissance, including: obtaining a set of parameters from a set of patient tags and a set of care provider tags in at least one of a set of predetermined locations, each set of parameters describing activities involving a set of patients and a set of care providers identified by the patient and care provider tags; associating each set of parameters with an identifier of the corresponding predetermined location; and receiving the parameters from the predetermined locations and in response generating depictions of activities of the patients and care providers.